-  ATG-031, discovered and developed in-house by Antengene, is the world's first anti-CD24 antibody to advance to the clinic in oncology and Antengene's third drug candidate to enter clinical studies in the U.S.

-  The Phase I "PERFORM" study will evaluate the safety and tolerability, pharmacology, immunogenicity, and preliminary efficacy of ATG-031 in patients with advanced solid tumors or B-cell non-Hodgkin's lymphoma (B-NHL)

The PERFORM trial is a first-in-human, multi-center, open-label, Phase I dose-finding study of ATG-031 in patients with advanced solid tumors or B-NHL. The primary objective of the study is to evaluate the safety and tolerability of ATG-031 as a monotherapy, and to determine the appropriate dose for Phase II studies. The secondary objective is to characterize the pharmacology, evaluate the immunogenicity, and assess the preliminary efficacy of ATG-031.

ATG-031 is a first-in-class humanized anti-CD24 monoclonal antibody which inhibits the "don't eat me" signal in the tumor microenvironment (TME). ATG-031 was designed to specifically bind with the CD24 expressed on cancer cells with high affinity and block the interaction between CD24 and the Siglec-10 receptor expressed on the surface of tumor associated macrophages (TAMs), to enhance the macrophage-mediated phagocytosis of cancer cells and promote cytotoxic T-cell function in the tumor microenvironment.

"Targeting the so-called 'don't eat me' signal is a promising therapeutic strategy for cancer treatment. In comparison to existing 'don't eat me' blockers such as anti-CD47 monoclonal antibodies, ATG-031 demonstrated a wider therapeutic window and the ability to overcome the on-target-off-tumor toxicities observed with CD47 inhibitors," said Dr. Bing Hou, Antengene's Executive Director of Drug Discovery and a co-inventor of ATG-031. "CD24 is a small and highly glycosylated protein that makes the development of antibodies particularly challenging. Through our persistent experimental efforts and by adopting unique discovery and screening strategies as well as leveraging our deep expertise on the target's biology, Antengene's discovery scientists  successfully advanced ATG-031, an antibody with optimal characteristics, into clinical development in just three years. We are thrilled to see our in-house developed first-in-class drug entering the clinic and taking a major step towards benefiting patients."

 "We believe that therapies that can effectively mobilize the macrophage activity in the tumor microenvironment will be a very important element of cancer care," said Dr. Bo Shan, Antengene's Chief Scientific Officer. "The potential role of ATG-031 is supported by robust preclinical data that showed potent single agent in vivo efficacy and synergistic effects with chemotherapy or checkpoint inhibitors (CPIs). Therefore, we are very optimistic about the clinical development of ATG-031 and look forward to initiating the patient enrolment as early as possible." 

"In this clinical program for ATG-031, we will deploy an in-house developed companion diagnostic (CDx) antibody, thus adding a precision-medicine element to the program," said Dr. Amily Zhang, Antengene's Chief Medical Officer. "In addition to serving as a patient selection tool, the CDx antibody will help us to better understand the CD24 expression in normal and cancerous tissue. We are excited to learn more about the safety, tolerability and efficacy of ATG-031 through the clinical program and look forward to sharing the first data from this study in 2024." 

"ATG-031 is the world's first anti-CD24 antibody to be advanced to the clinic in oncology and Antengene's third drug candidate cleared to enter clinical studies in the U.S.," said Dr. Jay Mei, Antengene's Founder, Chairman and CEO. "I am very proud of the entire R&D organization, for innovating and advancing this proprietary asset, from bench to patient, in such a robust and efficient manner. We believe that targeting CD24 could represent a major oncological advancement and anticipate more exciting progress with this clinical program."